Edgen Stock·Sep 12 2025, 18:08戻る
戻る
Novartis to Acquire Tourmaline Bio for $1.4 Billion, Enhancing Cardiovascular Pipeline
Edgen Stock·Sep 12 2025, 18:08
[1] Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action (TRML) | Seeking Alpha[2] Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)[3] The Strategic Rationale for Novartis' $1.4B Acquisition of Tourmaline Bio and the Long-Term Value of Pacibekitug in Cardiovascular and Autoimmune Diseases - AInvest